Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 10/20 | 0.45 |
| ▸ | MAOA | P21397 | 7/20 | 0.45 |
| ▸ | MAOB | P27338 | 7/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | RCOR1 | Q9UKL0 | 3/20 | 0.36 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20707745 | 1.00 | KDM1A (0.45) | KDM1AMAOAMAOBALDH1A1LMNA | |
| SCHEMBL20707778 | 1.00 | KDM1A (0.45) | KDM1AMAOAMAOBALDH1A1LMNA | |
| SCHEMBL22335046 | 0.84 | KDM1A (0.65) | KDM1AMAOAMAOBALDH1A1LMNA | |
| SCHEMBL20707753 | 0.78 | MAOB (0.45) | KDM1AMAOAMAOBALDH1A1MEN1 | |
| SCHEMBL25212520 | 0.76 | KDM1A (0.45) | KDM1AMAOAMAOBRCOR1 | |
| SCHEMBL30695906 | 0.76 | DDB1 (0.40) | KDM1AMAOAMAOBALDH1A1LMNA | |
| SCHEMBL28829898 | 0.76 | ESR2 (0.44) | KDM1AMAOAMAOB | |
| SCHEMBL4339855 | 0.76 | KDM1A (0.53) | KDM1AMAOAMAOBLMNAMEN1 | |
| SCHEMBL20149044 | 0.76 | KDM1A (0.53) | KDM1AMAOAMAOBRCOR1 | |
| SCHEMBL9779916 | 0.76 | LMNA (0.42) | KDM1AMAOAMAOBALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026102082-A1 | ALKYLPHENYL SUBSTITUTED COMPOUNDS, COMPOSITIONS AND METHODS OF USE | DEEP APPLE THERAPEUTICS, INC. (US) | 2026-05-15 | — | — | WO | disclosed |
| US-20260132119-A1 | Alkylphenyl Substituted Compounds, Compositions and Methods of Use | DEEP APPLE THERAPEUTICS, INC. (US) | 2026-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260132119-A1 | Alkylphenyl Substituted Compounds, Compositions and Methods of Use | GIPR, MC2R, GRPR | KDM1A 4734/4885MAOA 2344/4885MAOB 1534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.